Biogen Alzheimer's treatment becomes affordable with the PI System
- BenefitsNew reports simplify the quality assurance process and reduce number of delays in product delivery.
- ChallengeBatch reports delivered large amounts of irrelevant data, requiring lengthy manual review and slowing down product release process.
- SolutionA digital twin of oil field assets to run advanced algorithms and production simulations.
A next generation manufacturing process
While Biogen has made significant progress in the fight against Alzheimer’s, it’s goal is to treat one million more patients by 2020. To do so, the drug needed to become more affordable, and affordability starts with production. With a long-term goal of reducing its biologics manufacturing process by 80 percent and cutting costs from $10,000 per gram to $100-150 per gram, the team created a Next Generation Manufacturing plan for its Solothurn, Switzerland facility. Comprised of two cells and four bioreactors, the modular facility is designed to expand to manage additional Aducanumab production. However, the current process needed to be honed, and with the help of the PI System, it became possible.
To drastically increase output and reduce costs, Biogen needed to minimize screening time for raw materials while still maintaining quality, implement process and quality controls, as well as predictive models for consistency assessment. “When we look at our current processes… although we’ve worked really hard to optimize them, we still have some challenges, right?” said Tim Alosi, head of the Global Data Analytics team, during the 2017 OSIsoft User’s Conference in London. “…with next gen manufacturing, our goals bring together some of these initiatives and enable them with strong, integrated IT systems.”